BostonGene, a pioneer in developing AI foundation models for cancer and the immune system, has announced its participation in the 21st Annual Industry/Academia Precision Oncology & RadMed Symposium, a premier event bringing together global leaders in life sciences to discuss breakthroughs in AI, immuno-oncology, molecular imaging, and targeted therapies. The symposium will take place on November 5 at The Alexandria at Torrey Pines Conference Center in San Diego, California.
At the event, BostonGene will present a session titled “Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery.” The presentation will showcase how the company’s advanced foundation model seamlessly integrates genomic, transcriptomic, immune, and clinical data to uncover biologically grounded insights that inform therapeutic development, guide precision treatment strategies, and ultimately improve patient outcomes.
Through real-world applications and case studies, BostonGene will illustrate how its AI-driven approach enables the integration of complex molecular and clinical datasets to accelerate biomarker discovery, identify novel therapeutic targets, and optimize patient stratification, supporting both trial design and translational research success.
“The 21st Annual Industry/Academia Precision Oncology & RadMed Symposium provides a unique opportunity to highlight how omnimodal AI is reshaping the way we approach cancer research and treatment,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “By integrating diverse biological and clinical data types, BostonGene’s solutions deliver the insights necessary to match patients with the right therapies, de-risk development and accelerate drug development.”
BostonGene’s participation underscores its mission to harness the power of AI-driven, multi-dimensional data integration to transform the landscape of precision oncology and advance the next generation of personalized cancer care.
Also Read